- Home
- LDWY vs PRPO Comparison
LDWY vs PRPO Comparison
Compare LDWY & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- PRPO
- Stock Information
- Founded
- LDWY 1990
- PRPO N/A
- Country
- LDWY United States
- PRPO United States
- Employees
- LDWY N/A
- PRPO 57
- Industry
- LDWY Advertising
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- LDWY Consumer Discretionary
- PRPO Industrials
- Exchange
- LDWY Nasdaq
- PRPO Nasdaq
- Market Cap
- LDWY 6.7M
- PRPO 9.5M
- IPO Year
- LDWY 1991
- PRPO N/A
- Fundamental
- Price
- LDWY $3.42
- PRPO $6.59
- Analyst Decision
- LDWY
- PRPO
- Analyst Count
- LDWY 0
- PRPO 0
- Target Price
- LDWY N/A
- PRPO N/A
- AVG Volume (30 Days)
- LDWY 9.9K
- PRPO 7.9K
- Earning Date
- LDWY 11-11-2024
- PRPO 11-11-2024
- Dividend Yield
- LDWY N/A
- PRPO N/A
- EPS Growth
- LDWY N/A
- PRPO N/A
- EPS
- LDWY N/A
- PRPO N/A
- Revenue
- LDWY $24,813,000.00
- PRPO $16,719,999.00
- Revenue This Year
- LDWY N/A
- PRPO $75.18
- Revenue Next Year
- LDWY N/A
- PRPO N/A
- P/E Ratio
- LDWY N/A
- PRPO N/A
- Revenue Growth
- LDWY N/A
- PRPO 52.61
- 52 Week Low
- LDWY $3.02
- PRPO $4.31
- 52 Week High
- LDWY $6.88
- PRPO $8.99
- Technical
- Relative Strength Index (RSI)
- LDWY 46.04
- PRPO 52.82
- Support Level
- LDWY $3.34
- PRPO $6.42
- Resistance Level
- LDWY $3.66
- PRPO $6.99
- Average True Range (ATR)
- LDWY 0.20
- PRPO 0.33
- MACD
- LDWY 0.04
- PRPO -0.04
- Stochastic Oscillator
- LDWY 62.50
- PRPO 69.91
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two Industry Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.